Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $31 | $25 | $15 | $2 |
| % Growth | 21.6% | 66% | 793.2% | – |
| Cost of Goods Sold | $2 | $0 | $1 | $51 |
| Gross Profit | $29 | $25 | $14 | -$49 |
| % Margin | 93.8% | 98.7% | 90.4% | -2,839.8% |
| R&D Expenses | $99 | $80 | $74 | $51 |
| G&A Expenses | $0 | $0 | $37 | $19 |
| SG&A Expenses | $61 | $57 | $37 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $1 | -$0 |
| Operating Expenses | $161 | $138 | $111 | $70 |
| Operating Income | -$131 | -$113 | -$97 | -$68 |
| % Margin | -424.3% | -442.7% | -631.7% | -3,954.4% |
| Other Income/Exp. Net | -$11 | $96 | -$2 | $0 |
| Pre-Tax Income | -$143 | -$16 | -$99 | -$67 |
| Tax Expense | -$2 | $3 | $0 | $0 |
| Net Income | -$141 | -$20 | -$102 | -$67 |
| % Margin | -456.3% | -77.8% | -662.5% | -3,879% |
| EPS | -2.63 | -0.51 | -2.77 | -2.44 |
| % Growth | -415.7% | 81.6% | -13.5% | – |
| EPS Diluted | -2.63 | -0.51 | -2.77 | -2.44 |
| Weighted Avg Shares Out | 54 | 39 | 37 | 27 |
| Weighted Avg Shares Out Dil | 54 | 39 | 37 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $2 | $0 | $0 |
| Interest Expense | $17 | $11 | $3 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$125 | -$5 | -$96 | -$67 |
| % Margin | -405% | -20% | -622.5% | -3,892.7% |